OriCell’s Ori-C101 Advances to Phase II Trial in Liver Cancer
SHANGHAI, China, June 8, 2026 OriCell Therapeutics has achieved a major regulatory and clinical milestone with the National Medical...
ASCO 2026
Advertisement
AstraZeneca’s Camizestrant Extends Survival in ESR1-Mutant Breast Cancer
CHICAGO, Illinois, USA, June 2, 2026 AstraZeneca has announced compelling new results from its pivotal Phase III SERENA-6 trial,...
Stelexis BioSciences Reports Breakthrough Phase 1 Eganelisib Results in AML and MDS
WALTHAM, Massachusetts, USA, June 2, 202 Stelexis BioSciences has announced encouraging Phase 1 clinical trial results for eganelisib, its...
Celcuity’s Gedatolisib Doubles Progression-Free Survival in Phase 3 Breast Cancer Trial
MINNEAPOLIS, Minnesota, USA , June 2, 2026 Celcuity has announced groundbreaking results from the Phase 3 VIKTORIA-1 clinical trial,...
ImmunityBio Highlights ANKTIVA Data in Lung and Bladder Cancer at ASCO 2026
CULVER CITY, Calif., June 1, 2026 ImmunityBio announced new clinical and comparative data from its ANKTIVA® (nogapendekin alfa inbakicept-pmln)...
Advertisements
Telix Presents Encouraging Phase 3 Results for TLX591-Tx at ASCO 2026
MELBOURNE, Australia & INDIANAPOLIS, U.S., June 2, 2026 Telix Pharmaceuticals announced positive Part 1 data from its global Phase...
Karyopharm Highlights Phase 3 SENTRY Trial Progress in Myelofibrosis
NEWTON, Mass., June 1, 2026 Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading...
Ono’s ONO-4578 Improves Progression-Free Survival in Gastric Cancer Phase 2 Study
OSAKA, Japan, June 2, 2026 Ono Pharmaceutical announced positive Phase 2 clinical trial results for ONO-4578, its investigational oral...
Paradigm Health Advances Oncology Research with SPIRE-Powered ASCO Study
COLUMBUS, Ohio and CHICAGO, June 1, 2026 Paradigm Health has announced the successful implementation of its SPIRE (Scalable Platform...
Greywolf Reports Durable Responses with First-in-Class ERAP1 Inhibitor
OXFORD, UK, May 22, 2026 Greywolf Therapeutics announced encouraging clinical results from the Phase 1b portion of its ongoing...
Advertisement
